RU2353353C2 - Композиция антагониста vegf и антипролиферативного средства - Google Patents
Композиция антагониста vegf и антипролиферативного средства Download PDFInfo
- Publication number
- RU2353353C2 RU2353353C2 RU2006105496/15A RU2006105496A RU2353353C2 RU 2353353 C2 RU2353353 C2 RU 2353353C2 RU 2006105496/15 A RU2006105496/15 A RU 2006105496/15A RU 2006105496 A RU2006105496 A RU 2006105496A RU 2353353 C2 RU2353353 C2 RU 2353353C2
- Authority
- RU
- Russia
- Prior art keywords
- vegf
- agent
- fcδc1
- antiproliferative agent
- group
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 38
- 230000001028 anti-proliverative effect Effects 0.000 title claims abstract description 37
- 239000005557 antagonist Substances 0.000 title claims abstract description 32
- 150000001875 compounds Chemical class 0.000 title abstract description 17
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 title 1
- 101150030763 Vegfa gene Proteins 0.000 title 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 87
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 87
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 47
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 47
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 47
- 238000011282 treatment Methods 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 26
- 201000011510 cancer Diseases 0.000 claims abstract description 23
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims abstract description 12
- 230000004614 tumor growth Effects 0.000 claims abstract description 12
- 229960004562 carboplatin Drugs 0.000 claims abstract description 10
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract description 10
- 229960004316 cisplatin Drugs 0.000 claims abstract description 10
- 229960003668 docetaxel Drugs 0.000 claims abstract description 10
- 229950010897 iproplatin Drugs 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 8
- 230000000694 effects Effects 0.000 claims abstract description 7
- 190000008236 carboplatin Chemical compound 0.000 claims abstract 7
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 66
- 239000000203 mixture Substances 0.000 claims description 20
- 239000002246 antineoplastic agent Substances 0.000 claims description 18
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 18
- 229940127089 cytotoxic agent Drugs 0.000 claims description 17
- 229910052697 platinum Inorganic materials 0.000 claims description 9
- 102000029749 Microtubule Human genes 0.000 claims description 7
- 108091022875 Microtubule Proteins 0.000 claims description 7
- 210000004688 microtubule Anatomy 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 239000005022 packaging material Substances 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000008177 pharmaceutical agent Substances 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 25
- 239000000126 substance Substances 0.000 abstract description 10
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 229940127554 medical product Drugs 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 11
- 238000002512 chemotherapy Methods 0.000 description 9
- 206010003445 Ascites Diseases 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 238000010171 animal model Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 231100000682 maximum tolerated dose Toxicity 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 240000002022 Anthriscus cerefolium Species 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000202349 Taxus brevifolia Species 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229940063683 taxotere Drugs 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010059766 Haemorrhagic ascites Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- -1 etc. Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical class CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49000203P | 2003-07-25 | 2003-07-25 | |
| US60/490,002 | 2003-07-25 | ||
| US49397103P | 2003-08-08 | 2003-08-08 | |
| US60/493,971 | 2003-08-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006105496A RU2006105496A (ru) | 2006-06-10 |
| RU2353353C2 true RU2353353C2 (ru) | 2009-04-27 |
Family
ID=34118812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006105496/15A RU2353353C2 (ru) | 2003-07-25 | 2004-07-23 | Композиция антагониста vegf и антипролиферативного средства |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7354579B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1648428A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5355856B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101175990B1 (cg-RX-API-DMAC7.html) |
| AR (1) | AR046510A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004261165C1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0412798A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2529742C (cg-RX-API-DMAC7.html) |
| IL (1) | IL172406A (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA05013642A (cg-RX-API-DMAC7.html) |
| MY (1) | MY149169A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20060924L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ544570A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2353353C2 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI351953B (cg-RX-API-DMAC7.html) |
| UY (1) | UY28438A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005011734A2 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2597973C2 (ru) * | 2010-03-26 | 2016-09-20 | Ф. Хоффманн-Ля Рош Аг | Биспецифические двухвалентные антитела анти-vegf/анти-ang-2 |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| JP4303105B2 (ja) * | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | 二重特異性リガンドとその利用 |
| US20100234570A1 (en) * | 2001-06-28 | 2010-09-16 | Domantis Limited | Ligand |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| CN1678634A (zh) * | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| CA2511910A1 (en) * | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| CA2519875C (en) * | 2003-06-06 | 2014-01-14 | Regeneron Pharmaceuticals, Inc. | Method of tumor regression with vegf inhibitors |
| FR2878749B1 (fr) * | 2004-12-03 | 2007-12-21 | Aventis Pharma Sa | Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives |
| EP1853298A2 (en) * | 2005-02-11 | 2007-11-14 | Regeneron Pharmaceuticals, Inc. | Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| CN103169729A (zh) | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| CA3142945A1 (en) * | 2005-03-25 | 2006-10-05 | Regeneron Pharmaceuticals, Inc. | Histidine-buffered formulations of vegf antagonist |
| CA2632866A1 (en) * | 2005-12-01 | 2007-06-07 | Domantis Limited | Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1 |
| FR2895258B1 (fr) * | 2005-12-22 | 2008-03-21 | Aventis Pharma Sa | Combinaison comprenant de la combretastatine et des agents anticancereux |
| ES2828739T3 (es) | 2006-04-07 | 2021-05-27 | Aerpio Pharmaceuticals Inc | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos |
| US20080045589A1 (en) * | 2006-05-26 | 2008-02-21 | Susan Kelley | Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer |
| CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| AU2008224929A1 (en) * | 2007-03-14 | 2008-09-18 | Mayo Foundation For Medical Education And Research | Treating skin cancer |
| CA2683801A1 (en) * | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
| FR2918279B1 (fr) * | 2007-07-05 | 2010-10-22 | Aventis Pharma Sa | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
| LT5610B (lt) | 2007-12-17 | 2009-11-25 | Uab Baltec Cnc Technologies, , | Kompleksinė sveikatinimo ir sporto įrangos sistema ir jos įgyvendinimo būdas |
| ES2531322T3 (es) * | 2008-06-17 | 2015-03-13 | Wyeth Llc | Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina |
| WO2010005527A1 (en) | 2008-06-30 | 2010-01-14 | Angioblast Systems, Inc. | Treatment of eye diseases and excessive neovascularization using a combined therapy |
| EP3266453A1 (en) | 2008-07-03 | 2018-01-10 | Mayo Foundation for Medical Education and Research | Treating cancer |
| BRPI1006897A2 (pt) | 2009-07-06 | 2015-09-08 | Akebia Therapeutics Inc | compostos, composições e métodos de prevenção da metástase de células cancerosas. |
| US9393318B2 (en) | 2010-03-29 | 2016-07-19 | Abraxis Bioscience, Llc | Methods of treating cancer |
| KR20130028727A (ko) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| KR20130088116A (ko) | 2010-06-04 | 2013-08-07 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| KR20180023015A (ko) | 2011-01-13 | 2018-03-06 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| HUE048876T2 (hu) | 2011-05-09 | 2020-08-28 | Mayo Found Medical Education & Res | Rákos megbetegedések kezelése |
| JP2014516075A (ja) | 2011-06-06 | 2014-07-07 | シェブロン フィリップス ケミカル カンパニー エルピー | 癌治療のためのメタロセン化合物の使用 |
| MX363351B (es) | 2011-10-13 | 2019-03-20 | Aerpio Therapeutics Inc | Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular. |
| US10413606B2 (en) | 2012-10-01 | 2019-09-17 | Mayo Foundation For Medical Education And Research | Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| WO2015138882A1 (en) | 2014-03-14 | 2015-09-17 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
| TWI743024B (zh) | 2014-06-06 | 2021-10-21 | 美商健臻公司 | 灌注培養方法及其用途 |
| EP3154586B1 (en) | 2014-06-13 | 2020-05-27 | Mayo Foundation for Medical Education and Research | Treating lymphomas |
| US10213513B2 (en) | 2014-06-16 | 2019-02-26 | Mayo Foundation For Medical Education And Research | Treating myelomas |
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| RS58957B1 (sr) | 2014-07-18 | 2019-08-30 | Sanofi Sa | Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka |
| CN107073132B (zh) | 2014-10-06 | 2021-08-27 | 梅约医学教育与研究基金会 | 载体-抗体组合物及其制备和使用方法 |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| CN113713101B (zh) | 2015-09-23 | 2023-07-28 | 视点制药公司 | 用tie-2的激活剂治疗眼内压的方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| WO2017120501A1 (en) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon |
| EP3414330A4 (en) | 2016-02-08 | 2019-07-03 | Vitrisa Therapeutics, Inc. | COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF TIME AND USES THEREOF |
| US11351254B2 (en) | 2016-02-12 | 2022-06-07 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| EP3432928A4 (en) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC |
| WO2017165440A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| CN109310756B (zh) * | 2016-05-13 | 2022-06-28 | 奥美药业有限公司 | 新型血管生成素2，vegf双特异性拮抗剂 |
| US11059885B2 (en) | 2016-05-13 | 2021-07-13 | Askgene Pharma Inc. | Angiopoietin 2, VEGF dual antagonists |
| CN109890419A (zh) | 2016-09-01 | 2019-06-14 | 梅约医学教育与研究基金会 | 用于治疗癌症的载体-pd-l1结合剂组合物 |
| CN109843336A (zh) | 2016-09-01 | 2019-06-04 | 梅约医学教育与研究基金会 | 用于靶向t细胞癌症的方法和组合物 |
| US11590098B2 (en) | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| CN109843924A (zh) | 2016-09-06 | 2019-06-04 | 梅约医学教育与研究基金会 | 治疗表达pd-l1的癌症的方法 |
| AU2017324947A1 (en) | 2016-09-06 | 2019-03-28 | Mayo Foundation For Medical Education And Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
| WO2018160917A1 (en) | 2017-03-03 | 2018-09-07 | Janssen Biotech, Inc. | Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer |
| KR20200093621A (ko) | 2017-11-30 | 2020-08-05 | 리제너론 파아마슈티컬스, 인크. | 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| US11524053B2 (en) | 2018-01-26 | 2022-12-13 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| RS67656B1 (sr) | 2018-05-10 | 2026-02-27 | Regeneron Pharma | Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora |
| JP7564824B2 (ja) | 2019-04-29 | 2024-10-09 | アイポイント ファーマシューティカルズ， インコーポレイテッド | シュレム管を標的とするＴｉｅ－２活性化物質 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN114867487A (zh) | 2019-11-25 | 2022-08-05 | 加利福尼亚大学董事会 | 用于眼内新生血管的长效vegf抑制剂 |
| MX2022013812A (es) | 2020-05-08 | 2022-12-15 | Regeneron Pharma | Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer. |
| FI4185318T3 (fi) | 2021-05-17 | 2025-10-13 | Regeneron Pharma | Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon |
| US20230295266A1 (en) | 2022-03-15 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders |
| TW202400214A (zh) | 2022-03-15 | 2024-01-01 | 美商再生元醫藥公司 | 用於血管新生眼睛病症之治療之延長高劑量ｖｅｇｆ拮抗劑方案 |
| CN121712520A (zh) | 2023-06-23 | 2026-03-20 | 瑞泽恩制药公司 | 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案 |
| WO2025217334A1 (en) | 2024-04-09 | 2025-10-16 | Regeneron Pharmaceuticals, Inc. | Low concentration vegf receptor fusion protein containing formulations |
| KR20260096819A (ko) | 2024-12-13 | 2026-06-24 | 리제너론 파아마슈티컬스, 인크. | 망막 정맥 폐쇄에 속발하는 혈관신생 눈 장애의 치료를 위한 연장된 고용량 vegf 길항제 레지먼 |
| WO2026148214A1 (en) | 2025-01-02 | 2026-07-09 | Regeneron Pharmaceuticals, Inc. | High concentration vegf receptor fusion protein containing buffer free formulations |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000075319A1 (en) * | 1999-06-08 | 2000-12-14 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US6342219B1 (en) * | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody compositions for selectively inhibiting VEGF |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6811779B2 (en) * | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
| US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| CA2519875C (en) * | 2003-06-06 | 2014-01-14 | Regeneron Pharmaceuticals, Inc. | Method of tumor regression with vegf inhibitors |
-
2004
- 2004-07-21 AR ARP040102585A patent/AR046510A1/es unknown
- 2004-07-23 KR KR1020067000521A patent/KR101175990B1/ko not_active Expired - Lifetime
- 2004-07-23 MY MYPI20042968A patent/MY149169A/en unknown
- 2004-07-23 WO PCT/US2004/023815 patent/WO2005011734A2/en not_active Ceased
- 2004-07-23 TW TW093121978A patent/TWI351953B/zh not_active IP Right Cessation
- 2004-07-23 AU AU2004261165A patent/AU2004261165C1/en not_active Expired
- 2004-07-23 MX MXPA05013642A patent/MXPA05013642A/es not_active Application Discontinuation
- 2004-07-23 EP EP04779050A patent/EP1648428A2/en not_active Withdrawn
- 2004-07-23 RU RU2006105496/15A patent/RU2353353C2/ru active
- 2004-07-23 US US10/897,802 patent/US7354579B2/en not_active Expired - Lifetime
- 2004-07-23 CA CA2529742A patent/CA2529742C/en not_active Expired - Lifetime
- 2004-07-23 BR BRPI0412798-6A patent/BRPI0412798A/pt not_active Application Discontinuation
- 2004-07-23 JP JP2006521281A patent/JP5355856B2/ja not_active Expired - Lifetime
- 2004-07-23 NZ NZ544570A patent/NZ544570A/en not_active IP Right Cessation
- 2004-07-26 UY UY28438A patent/UY28438A1/es not_active Application Discontinuation
-
2005
- 2005-12-06 IL IL172406A patent/IL172406A/en not_active IP Right Cessation
-
2006
- 2006-02-24 NO NO20060924A patent/NO20060924L/no not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6342219B1 (en) * | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody compositions for selectively inhibiting VEGF |
| WO2000075319A1 (en) * | 1999-06-08 | 2000-12-14 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
Non-Patent Citations (1)
| Title |
|---|
| Руководство по медицине «THE MERCK MANUAL». - M,: Мир 1997, т.2, с.867-870. ЭНЦИКЛОПЕДИЯ ЛЕКАРСТВ. - M.: РЛС 2001 с.661. Справочник Противоопухолевая терапия Под ред. Переводчиковой Н.И. - M.: Медицина, 1993, с.86-87. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2597973C2 (ru) * | 2010-03-26 | 2016-09-20 | Ф. Хоффманн-Ля Рош Аг | Биспецифические двухвалентные антитела анти-vegf/анти-ang-2 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20060028654A (ko) | 2006-03-30 |
| MY149169A (en) | 2013-07-31 |
| US7354579B2 (en) | 2008-04-08 |
| AU2004261165C1 (en) | 2009-12-17 |
| JP5355856B2 (ja) | 2013-11-27 |
| TWI351953B (en) | 2011-11-11 |
| CA2529742A1 (en) | 2005-02-10 |
| CA2529742C (en) | 2012-09-18 |
| AR046510A1 (es) | 2005-12-14 |
| US20050032699A1 (en) | 2005-02-10 |
| AU2004261165B2 (en) | 2009-07-16 |
| WO2005011734A3 (en) | 2005-04-14 |
| UY28438A1 (es) | 2004-11-08 |
| EP1648428A2 (en) | 2006-04-26 |
| IL172406A0 (en) | 2006-04-10 |
| MXPA05013642A (es) | 2006-03-10 |
| BRPI0412798A (pt) | 2006-09-26 |
| JP2007500131A (ja) | 2007-01-11 |
| KR101175990B1 (ko) | 2012-08-23 |
| TW200524589A (en) | 2005-08-01 |
| AU2004261165A1 (en) | 2005-02-10 |
| NZ544570A (en) | 2008-08-29 |
| RU2006105496A (ru) | 2006-06-10 |
| IL172406A (en) | 2016-04-21 |
| WO2005011734A2 (en) | 2005-02-10 |
| NO20060924L (no) | 2006-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5355856B2 (ja) | Ｖｅｇｆアンタゴニストおよび抗増殖性薬剤の組成物ならびに癌の処置のためのその使用 | |
| TW202529777A (zh) | 組合療法 | |
| JP2022095894A (ja) | 薬学的組成物及び方法 | |
| JP5650639B2 (ja) | 腫瘍疾患の治療 | |
| KR20070097495A (ko) | 섬유화 억제를 위한 약물 담체 및 약물 담체 키트 | |
| US20210254069A1 (en) | Combination therapies comprising c/ebp alpha sarna | |
| US20050112061A1 (en) | Use of a VEGF antagonist in combination with radiation therapy | |
| US20050196340A1 (en) | Use of a VEGF antagonist in combination with radiation therapy | |
| MX2009001233A (es) | Metodos, composiciones y articulos de manufactura para contribuir al tratamiento de canceres. | |
| JP7780824B2 (ja) | Ｈｅｒ２ワクチン組成物 | |
| US20240207304A1 (en) | Combination Therapies Comprising C/EBP Alpha saRNA | |
| US20210024928A1 (en) | C/ebp alpha sarna compositions and methods of use | |
| WO2006091767A2 (en) | Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors | |
| ZA200600158B (en) | Composition of a VEGF antagonist and an anti-proliferative agent and its use for the treatment of cancer | |
| CN104961831A (zh) | 一种修饰的重组人内皮抑素及其应用 | |
| CN121622853A (zh) | 一种靶向atad3a磷酸化的多肽联合阿霉素在制备肺癌治疗药物中的应用 | |
| JP6137527B2 (ja) | 癌治療または癌緩和ケア用オクトレオチド修飾ナノ製剤 | |
| CN112168971B (zh) | 抗vegf抗体和pdgf/pdgfr抑制剂在制备治疗表达fgf2肿瘤的药物的应用 | |
| KR20250036992A (ko) | Pld1 활성을 억제하는 항암 펩타이드를 포함하는 암세포 증식 억제용 조성물 및 약학 조성물 | |
| CN112168960A (zh) | 抗VEGF抗体和抗ANG2抗体在制备治疗具有Ras突变的肿瘤的药物中的应用 | |
| ES2453295T3 (es) | Composiciones para contribuir al tratamiento de cánceres | |
| CN118436642A (zh) | 干扰肿瘤Treg细胞分化的药物及其应用 | |
| CN121550252A (zh) | 双二羧酸二氨络铂抗癌药物 | |
| CN114605517A (zh) | 一种具有广谱抗癌作用的多肽lxp-7及其应用 | |
| CN120393048A (zh) | 一种肿瘤靶向药物递送系统及其药物包装方法 |